Patents Assigned to Incyte Corporation
  • TOPICAL FORMULATIONS OF RUXOLITINIB WITH AN ORGANIC AMINE PH ADJUSTING AGENT FOR TREATMENT OF SKIN DISEASES
    Publication number: 20230172937
    Abstract: The present disclosure relates to topical formulations and methods of treating skin diseases using topical formulations comprising a JAK 1/2 inhibitor, which is ruxolitinib, or a pharmaceutically acceptable salt thereof, and an organic amine pH adjusting agent. The skin diseases for treatment include, but are not limited to, psoriasis, atopic dermatitis, alopecia, vitiligo, Reiter's syndrome, pityriasis rubra pilaris, epidermolysis bullosa simplex, palmoplantar keratoderma, pachyonychia congenita, steatocystoma multiplex, cutaneous lichen planus, cutaneous T-cell lymphoma, hidradenitis suppurativa, contact dermatitis, ichthyosis, and a disorder of keratinization. The organic amine pH adjusting agent is a tertiary amine or an alkanol amine.
    Type: Application
    Filed: December 4, 2022
    Publication date: June 8, 2023
    Applicant: INCYTE CORPORATION
    Inventors: Naresh MODEPALLI, Trupti SHETH, Marc BROWN, Charles EVANS, James FIDGE, Florencia GUIDALI, Tecashanell McINTOSH, Vanessa COFRE
  • Bicyclic heterocycles as FGFR4 inhibitors
    Patent number: 11667635
    Abstract: The present invention relates to bicyclic heterocycles, and pharmaceutical compositions of the same, that are inhibitors of the FGFR4 enzyme and are useful in the treatment of FGFR4-associated diseases such as cancer.
    Type: Grant
    Filed: April 23, 2021
    Date of Patent: June 6, 2023
    Assignees: Incyte Corporation, Incyte Holdings Corporation
    Inventors: Liang Lu, Liangxing Wu, Ding-Quan Qian, Wenqing Yao
  • Tricyclic urea compounds as JAK2 V617F inhibitors
    Patent number: 11661422
    Abstract: The present application provides tricyclic urea compounds that modulate the activity of the V617F variant of JAK2, which are useful in the treatment of various diseases, including cancer.
    Type: Grant
    Filed: August 26, 2021
    Date of Patent: May 30, 2023
    Assignee: Incyte Corporation
    Inventors: Kai Liu, Brent Douty, Daniel Levy, Liangxing Wu, Wenqing Yao, Eddy W. Yue
  • MULTISPECIFIC BINDING MOIETIES COMPRISING PD-1 AND TGF-BRII BINDING DOMAINS
    Publication number: 20230159645
    Abstract: The present disclosure relates to a multispecific binding moiety comprising a PD-1 binding domain and a TGF-?RII binding domain, wherein the PD-1 binding domain blocks PD-1 mediated signaling and the TGF-?RII binding domain blocks TGF-?RII-mediated signaling. The present disclosure further relates to a pharmaceutical composition comprising such multispecific binding moiety, a method of treatment using such multispecific binding moiety, and a cell producing such multispecific binding moiety.
    Type: Application
    Filed: November 18, 2022
    Publication date: May 25, 2023
    Applicants: MERUS N.V., Incyte Corporation
    Inventors: Cecilia Anna Wilhelmina GEUIJEN, Patrick Mayes, Shaun M. Stewart, Liang-Chuan Wang
  • Methods of treating cancer with an FGFR inhibitor
    Patent number: 11628162
    Abstract: This application relates to methods of treating cancer in a patient in need thereof, comprising administering a Fibroblast Growth Factor Receptors (FGFR) inhibitor to the patient.
    Type: Grant
    Filed: March 6, 2020
    Date of Patent: April 18, 2023
    Assignee: Incyte Corporation
    Inventors: Tao Ji, Krishnaswamy Yeleswaram
  • Biomarkers for vitiligo
    Patent number: 11624751
    Abstract: Biomarkers are provided that are associated with or predictive of a subject's responsiveness to a JAK inhibitor. The biomarkers, compositions, and methods described herein are useful in selecting appropriate treatment modalities for a subject having, suspected of having, or at risk of developing vitiligo.
    Type: Grant
    Filed: March 18, 2020
    Date of Patent: April 11, 2023
    Assignee: Incyte Corporation
    Inventors: Michael D. Howell, Sherry Owens, Beth Rumberger, Huiqing Liu
  • Heterocyclic compounds as immunomodulators
    Patent number: 11613536
    Abstract: Disclosed are compounds of Formula (I), methods of using the compounds as immunomodulators, and pharmaceutical compositions comprising such compounds. The compounds are useful in treating, preventing or ameliorating diseases or disorders such as cancer or infections.
    Type: Grant
    Filed: May 4, 2021
    Date of Patent: March 28, 2023
    Assignee: Incyte Corporation
    Inventors: Liangxing Wu, Fenglei Zhang, Song Mei, Wenqing Yao
  • Bicyclic heterocycles as FGFR inhibitors
    Patent number: 11607416
    Abstract: The present invention relates to bicyclic heterocycles, and pharmaceutical compositions of the same, that are inhibitors of the FGFR enzyme and are useful in the treatment of FGFR-associated diseases such as cancer.
    Type: Grant
    Filed: October 14, 2020
    Date of Patent: March 21, 2023
    Assignee: Incyte Corporation
    Inventors: Oleg Vechorkin, Minh Nguyen, Chao Qi, Anlai Wang, Michael Witten, Yao Xu, Hai Fen Ye, Ke Zhang, Peng Zhao, Wenqing Yao
  • Heterocyclic compounds as immunomodulators
    Patent number: 11608337
    Abstract: Disclosed are compounds of Formula (I), methods of using the compounds as immunomodulators, and pharmaceutical compositions comprising such compounds. The compounds are useful in treating, preventing or ameliorating diseases or disorders such as cancer or infections.
    Type: Grant
    Filed: September 25, 2020
    Date of Patent: March 21, 2023
    Assignee: Incyte Corporation
    Inventors: Zhenwu Li, Liangxing Wu, Wenqing Yao
  • Topical treatment of vitiligo by a JAK inhibitor
    Patent number: 11602536
    Abstract: The present disclosure relates to topical treatment of vitiligo using ruxolitinib, or a pharmaceutically acceptable salt thereof.
    Type: Grant
    Filed: June 10, 2020
    Date of Patent: March 14, 2023
    Assignee: Incyte Corporation
    Inventors: Kathleen Butler, Jim Lee, Kang Sun, Fiona Kuo, Michael Howell
  • JAK1 pathway inhibitors for the treatment of gastrointestinal disease
    Patent number: 11596632
    Abstract: This disclosure relates to JAK1 pathway inhibitors and the use thereof in treating gastrointestinal diseases or disorders such as ulcerative colitis.
    Type: Grant
    Filed: December 19, 2019
    Date of Patent: March 7, 2023
    Assignee: Incyte Corporation
    Inventors: Krishnaswamy Yeleswaram, Paul Smith, Gregory F. Hollis
  • PD-L1/STING conjugates and methods of use
    Patent number: 11596692
    Abstract: The present application relates to conjugates of STING agonists and small molecule modulators of the PD-1/PD-L1 protein/protein interaction, as well as methods of treating cancer using the conjugates.
    Type: Grant
    Filed: November 21, 2019
    Date of Patent: March 7, 2023
    Assignee: Incyte Corporation
    Inventors: Liangxing Wu, Zhenwu Li, Wenqing Yao
  • Topical formulation for a JAK inhibitor
    Patent number: 11590136
    Abstract: This invention relates to pharmaceutical formulations for topical skin application comprising (R)-3-cyclopentyl-3-[4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-1H-pyrazol-1-yl]propanenitrile, or a pharmaceutically acceptable salt thereof, and use in the treatment of skin disorders.
    Type: Grant
    Filed: March 25, 2022
    Date of Patent: February 28, 2023
    Assignees: Incyte Corporation, Incyte Holdings Corporation
    Inventors: Bhavnish Parikh, Bhavesh Shah, Krishnaswamy Yeleswaram
  • Bipyrazole derivatives as JAK inhibitors
    Patent number: 11591318
    Abstract: The present invention provides compounds of Formula I: or pharmaceutically acceptable salts thereof, as well as their compositions and methods of use, that inhibit the activity of Janus kinase (JAK) and are useful in the treatment of diseases related to the activity of JAK including, for example, inflammatory disorders, autoimmune disorders, cancer, and other diseases.
    Type: Grant
    Filed: April 13, 2021
    Date of Patent: February 28, 2023
    Assignee: Incyte Corporation
    Inventors: Yun-Long Li, Jincong Zhuo, Ding-Quan Qian, Song Mei, Ganfeng Cao, Yongchun Pan, Qun Li, Zhongjiang Jia
  • Bicyclic heterocycles as FGFR inhibitors
    Patent number: 11591329
    Abstract: The present invention relates to bicyclic heterocycles, and pharmaceutical compositions of the same, that are inhibitors of the FGFR3 enzyme and are useful in the treatment of FGFR3-associated diseases such as cancer.
    Type: Grant
    Filed: July 8, 2020
    Date of Patent: February 28, 2023
    Assignee: Incyte Corporation
    Inventors: Oleg Vechorkin, Chao Qi, Minh Nguyen, Anlai Wang, Wenqing Yao
  • Topical treatment of vitiligo by a jak inhibitor
    Patent number: 11590138
    Abstract: The present disclosure relates to topical treatment of vitiligo using ruxolitinib, or a pharmaceutically acceptable salt thereof.
    Type: Grant
    Filed: July 8, 2022
    Date of Patent: February 28, 2023
    Assignee: Incyte Corporation
    Inventors: Kathleen Butler, Jim Lee, Kang Sun, Fiona Kuo, Michael Howell
  • Pyrrolotriazine compounds as TAM inhibitors
    Patent number: 11591338
    Abstract: This application relates to compounds of Formula I: or pharmaceutically acceptable salts thereof, which are inhibitors of TAM kinases which are useful for the treatment of disorders such as cancer.
    Type: Grant
    Filed: October 19, 2020
    Date of Patent: February 28, 2023
    Assignee: Incyte Corporation
    Inventors: Yun-Long Li, Xiaozhao Wang, Chunhong He
  • Ruxolitinib formulation for reduction of itch in atopic dermatitis
    Patent number: 11590137
    Abstract: This disclosure relates to methods of reducing itch in patients with atopic dermatitis and treating patients with atopic dermatitis by administering a topical 0.75% or 1.5% ruxolitinib cream two times per day.
    Type: Grant
    Filed: March 28, 2022
    Date of Patent: February 28, 2023
    Assignee: Incyte Corporation
    Inventors: Michael Kuligowski, Kang Sun, Michael Howell, May Grace E. Venturanza, Jim Lee
  • Biomarkers for inflammatory skin disease
    Patent number: 11584961
    Abstract: Biomarkers are provided that are predictive of a subject's responsiveness to a therapy comprising a JAK inhibitor. The biomarkers, compositions, and methods described herein are useful in selecting appropriate treatment modalities for a subject having, suspected of having, or at risk of developing an inflammatory skin disease.
    Type: Grant
    Filed: March 29, 2019
    Date of Patent: February 21, 2023
    Assignee: Incyte Corporation
    Inventors: Michael D. Howell, Huiqing Liu
  • Sustained-release dosage forms of ruxolitinib
    Patent number: 11576864
    Abstract: The present invention relates to sustained-release formulations and dosage forms of ruxolitinib, or a pharmaceutically acceptable salt thereof, which are useful in the treatment of Janus kinase-associated diseases such as myeloproliferative disorders.
    Type: Grant
    Filed: June 23, 2022
    Date of Patent: February 14, 2023
    Assignees: Incyte Corporation, Incyte Holdings Corporation
    Inventors: Yong Ni, Bhavnish Parikh, Krishnaswamy Yeleswaram, Susan Erickson-Viitanen, William V. Williams